Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T14:57:07.552Z.
Calculation as of: 2026-10-06T14:57:07.552Z.
Quote observation: 2026-10-06T14:50:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bcc3f1894ec499320e43c54a24f2662d6ad9e54feca4b92c79248349e67b8166
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Market Cap
$4.21M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.03M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.00M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.43M
Operating Cash Flow Yield
N/A
TTM Avg
3.14%
3Y Avg
3.14%
5Y Avg
3.14%
Market Cap
$4.57M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.58M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GRI Bio, Inc. (GRI) | $4.13M | N/A | N/A | N/A | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.21M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.03M | N/A | N/A | N/A | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.00M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.43M | N/A | 3.14% | 3.14% | 3.14% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.57M | N/A | N/A | N/A | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.58M | N/A | N/A | N/A | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.72M | N/A | N/A | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.78M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
